Investing in China equities in the Year of the Ox

China equities had a strong year in the Year of the Rat. So how should investors navigate China equities in the Year of the Ox? We sat down with Bin Shi, Head of China Equities, to discuss.

04 Feb 2021

1. How would you summarize 2020? 

2020 was a year of huge change and many challenges. It has forced most people to adapt to new realities.

2021 will likely also be a year of changes and challenges, which will create many winners and losers. We are optimistic about the Chinese equity market in the long run. There are many high quality companies with strong management which deliver sustainable growth.

2. What’s your strategy with cash?

Throughout the year, we have adhered to our investment philosophy and process and invested with discipline.

In 2020, markets rose and we were cautious about valuations in certain segments of the market that rose particularly quickly, such as the small and mid-cap names in IT and healthcare, electric vehicles (EVs) and biotech-related. We believe increased retail participation has led to exuberance in certain segments of the market.

Over the past couple of months there have been some positive developments on the macro front, such as progress on vaccines globally and the US election result, which have reduced the short-term headwinds for China, and we have been deploying cash to some of our high conviction ideas.

3. Which themes are you particularly focused on?

We believe our predominant exposure to long term, domestic themes should hold us in good stead.

These areas include China’s rebalancing into services and consumption, increasing share of discretionary spending and premiumization, and increasing spending on R&D and technology leading to innovations.

4. Is the China A-share market overvalued?

Investors should stay invested. The A-share market has, overall, done very well and some of the sectors have done even better.

If you look at the overall market, valuations are just above the 10-year historical average so from that perspective it is not so overheated.

If you look at the overall market, valuations are just above the 10-year historical average so from that perspective it is not so overheated.

In the A-share market you are either hot or not. Some sectors are very hot, but other sectors did not participate as much. We believe we can still find long-term opportunities in those other not so hot sectors. So we are actively deploying our money into the A-share market at this point.

5. What is your outlook for US/China relations under the Biden administration?

We have held the view that the US-China rivalry is not going away in a hurry, even if the incoming Biden administration might be more measured in dealing with such confrontational issues.

The key difference now is that the president's governing philosophy is different, and there will be differences in style and specific measures.

China is catching up very quickly, and it is expected that US measures against China will continue, but they will perhaps not be as extreme as those imposed on Huawei.

The reason is that, in the long run, harsh measures from the US will force China to actively develop its own technologies so that it can be independent.
And when that happens, the US will not only lose a huge market, but also create a strong competitor.

A more pragmatic approach for the two sides is "Coopetition" which means to cooperate and compete at the same time.

6. What impact have US/China tensions had on the A-share market?

There has been some impact, but not too much. The Chinese A-share market is driven by domestic investors and domestic liquidity and global investors’ participation is, at this point, still comparatively small.

US moves to limit investment in some specific companies has had some impact, but that vacuum has been quickly filled by domestic investors.

7. The Ant Financial IPO suspension and anti-trust legislation have been sizeable shocks to global investors, do you really think A-shares are ready to be unleashed on global investors just yet?

Definitely yes. You can’t just focus on isolated incidents like Ant Financial. A-shares are still not perfect, but neither are other markets. I believe the A-share market is still a good market in which to make money and generate a return.

On antitrust legislation, actually it was announced many years ago. What we are seeing now is stronger enforcement, which may have surprised people.

The reason behind it is that the internet platform companies are becoming very large indeed and their strategies can have major impacts on the whole country. As such, I believe there is a need for stronger enforcement of antitrust regulations.

8. What are your views on the potential relisting of Chinese companies in Hong Kong?

With regard to ADR relisting in Hong Kong, I think they should continue to be listed in the US because they have benefited from the deep pools of money there and have also benefited US investors too since they have performed extremely well.

The size of the opportunity for Hong Kong depends on how they are treated in the US. If the US regulators can reconcile the difference in accounting standards, I think they (ADRs) will continue to be listed there and potentially seek a secondary listing in Hong Kong, which is fine.

This will benefit investors because at this point I own both ADRs and secondary listed Hong Kong names, and I like the fact I can choose between the liquid market in the US and Hong Kong listings, which trade in my timezone.

This allows me to put ideas to work right away, instead of waiting for the US market to open. The ideal situation is to have a primary listing in the US and a secondary listing in Hong Kong and then let investors pick and choose whichever they prefer.

We will have to wait and see though. If Chinese companies are treated badly in the US and get unfair treatment, it is possible they will move their primary listing to Hong Kong, which has the potential to benefit local investors here tremendously.

9. What’s your view on recent and future trends for IPOs in the China equity space?

2020 has been an extremely active year for IPOs in the China equities space and we actively participated in many of them.

Structural changes in China have driven the new rounds of IPOs, with many new companies with new business models coming to market. We find many of these newly-IPO’d companies attractive from a long-term investment perspective.

We think 2021 will continue to be an active year in terms of new companies coming to market in China. Many of these companies used private equity funding to develop their business, but now they are mature enough to become public companies.

10. China has made a big commitment to be carbon neutral by 2060 – just how serious is the Chinese government about building environmental factors into policy making, and how is this creating opportunities in the equity markets?

When the Chinese government says something, they really mean it.

For the carbon neutral targets, I think they have done a lot of calculations and work behind the scenes to make sure that this is something they can live up to.

So I think they are very serious about this target and this most likely means more support for electric vehicles and renewable energy.

More insights

Subscribe now

Perspectives matter. Tune in to our insights.

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.